

ITALIAN SUMMIT ON PRECISION MEDICINE

Standards of care, therapeutic targets and future perspectives

Presidents: *Giuseppe Curigliano, Paolo Marchetti, Andrea Botticelli*

13 - 14 April 2026

Villa Aurelia - Largo di Porta San Pancrazio, 2 - Rome



ITALIAN SUMMIT ON PRECISION MEDICINE

Standards of care, therapeutic targets and future perspectives

Presidents: Giuseppe Curigliano, Paolo Marchetti, Andrea Botticelli

13 - 14 April 2026

Villa Aurelia - Largo di Porta San Pancrazio, 2 - Rome



Rationale

Personalizing cancer medicine depends on the implementation of personalized diagnostics and therapeutics.

Detailed genomic screening is likely to play a central role in this.

Personalized Medicine has been widely depicted as a striking innovation, that is able to reform the standard approach to disease management, replacing the one-size-fits-all scheme of medicine with a single-patient-sized medical intervention.

Personalized medicine promoters usually highlight its potential to combine a more effective health-care with cost containment, according to the following rules:

- monitoring of disease risks and more effective prevention;
- early intervention;
- selection of optimal therapy;
- reduction of trial-and-error prescribing and reduction of adverse drug reactions;
- exclusion of unnecessary drugs;
- therapeutic drug monitoring and disease progression/remission monitoring;
- increased patient compliance with therapy.

But, in spite of expectations, many unsolved practical issues, from technical and scientific to ethical, legal and economic topics, are slowing down the translation of personalized medicine principles into medical practice. Furthermore, wide adoption of personalized strategies also has to deal with the peculiar rules, policy and reimbursement system of each country.

Application of Personalized Medicine in the real world seems entangled by the unmet need to develop evidence-based guidelines.

The aim of the meeting, where we are expecting approximately 150/200 participants from Italy and Europe, is to discuss with leading key opinion leaders about the future prospects of precision medicine and precision oncology and their application in real-world practice.



Program

13 April 2026

08:30 - 09:00 Welcome reception

09:00 - 09:05 Opening remarks: Welcome and introduction
Giuseppe Curigliano, Paolo Marchetti, Andrea Botticelli

Institutional opening Remarks
Orazio Schillaci - Italian Minister of Health

SESSION 1

09:05 - 11:45 **Successes and Challenges in Precision Oncology**
Chairs: Giampaolo Tortora, Andrea Botticelli

Opening Lecture

09:05 - 09:25 Learning from identification and use of biomarkers in precision oncology
Lillian L. Siu

09:25 - 09:35 Q&A
All

09:35 - 09:55 Learning from the evolution of master protocols for clinical trials in precision oncology
Vivek Subbiah

09:55 - 10:05 Q&A
All

10:05 - 10:25 Designing smarter trials: precision medicine under FDA's project optimus
Timothy A. Yap

10:25 - 10:35 Q&A
All



10:35 - 11:05 Coffee break

Science Spotlight

11:05 - 11:35 Early cancer detection and cancer interception
Charles Swanton

11:35 - 11:45 Q&A
All

SESSION 2

11:45 - 13:15 **New strategies in Precision Oncology**
Chair: Ruggero De Maria Marchiano

11:45 - 12:05 Radioligand Therapeutics
Ken Herrmann

12:05 - 12:15 Q&A
All

12:15 - 12:35 Cell Therapy
Christian Blank

12:35 - 12:45 Q&A
All

12:45 - 13:05 Vaccines
Paolo Antonio Ascierto

13:05 - 13:15 Q&A
All

13:15 - 14:25 Lunch



SESSION 3

14:25 - 16:15

Next generation ADCs

Chairs: Sherene Loi, Paolo Antonio Ascierto

14:25 - 14:55

Understanding parity and lactiation immune responses in breast cancer

Sherene Loi

14:55 - 15:05

Q&A

All

15:05 - 15:25

Applications of AI in ADC development

Antonio Marra

15:25 - 15:35

Q&A

All

Science Spotlight

15:35 - 16:05

Update on advanced Breast Cancer

Giuseppe Curigliano

16:05 - 16:15

Q&A

All

16:15 - 16:45

Coffee break

SESSION 4

16:45 - 19:45

Hurdles in the regulatory and operational framework in Precision Oncology

Chairs: Nello Martini, Giuseppe Tonini

16:45 - 17:05

Challenges in precision oncology: Perspectives from an academia viewpoint

Giancarlo Pruneri

17:05 - 17:15

Q&A

All



17:15 - 17:35 Challenges in precision oncology: Perspectives from a pharma viewpoint

Cristian Massacesi

17:35 - 17:45 Q&A

All

17:45 - 18:05 Challenges in precision oncology: Perspectives from a biotech viewpoint

Alberto Bardelli

18:05 - 18:15 Q&A

All

18:15 - 18:35 Access to precision oncology globally

Raffaella Casolino

18:35 - 18:45 Q&A

All

Science Spotlight

18:45 - 19:05 "VelociSuite - from target identification to human therapeutic antibodies, addressing limitations and bottlenecks"

John Kerk

Dinner



14 April 2026

SESSION 5

09:00 - 10:30

Growing an ecosystem in precision oncology

Chairs: Massimo Di Maio, Cristian Massacesi

09:00 - 09:20

Accelerating precision oncology in health care and research

Raffaella Casolino

09:20 - 09:30

Q&A

All

09:30 - 09:50

Accelerating precision oncology through scientific societies

Clifford A. Hudis

09:50 - 10:00

Q&A

All

10:00 - 10:20

Accelerating precision oncology through scientific journals

Thomas Powles

10:20 - 10:30

Q&A

All

Science Spotlight

10:30 - 11:15

Adjuvant treatment in HR+ HER2 negative early breast cancer: how to tailor treatment

Giuseppe Curigliano

11:15 - 11:45

Coffee break



SESSION 6

11:45 - 12:25

ROME Award in Precision Oncology

Chairs: Andrea Botticelli, Giuseppe Curigliano, Paolo Marchetti

11:45 - 12:15

AI for precision medicine

Fabrice André

12:15 - 12:25

Q&A

All

SESSION 7

12:25 - 15:05

Implementation of Precision Oncology in clinical practice

Chairs: Robert Giovanni Nisticò, Giuseppe Curigliano

12:25 - 12:55

Framework(s) to implement access to precision oncology

Christoph Benedikt Westphalen

12:55 - 13:05

Q&A

All

13:05 - 13:25

How to build a precision oncology center: The model of the Institute for Personalized Cancer Therapy (IPCT)

Funda Meric-Bernstam

13:25 - 13:35

Q&A

All

13:35 - 14:35

Lunch

14:35 - 14:55

How to interrogate data from large precision oncology dataset

Edoardo Crimini, Simone Scagnoli

14:55 - 15:05

Q&A

All

15:05 - 15:55

Closing remarks

Giuseppe Curigliano, Paolo Marchetti



Speakers and Chairmen

Fabrice André

President-elect of the European Society for Medical Oncology (ESMO); Research Director Institut Gustave Roussy, Department of Medical Oncology - Villejuif - Paris (France)

Paolo Antonio Ascierto

Direttore U.O.C di Melanoma Immunoterapia Oncologica e Terapie Innovative Istituto Nazionale per lo Studio e la Cura dei Tumori di Napoli - Naples (Italy)

Alberto Bardelli

IFOM Scientific Director, Principal Investigator Genomics of Cancer and Targeted Therapies, Professor Dept. Of Oncology University of Turin - Turin (Italy)

Christian Blank

Group leader and clinical staff member, Netherlands Cancer Institut - Amsterdam (The Netherlands)

Andrea Botticelli

Associate Professor Dept of Radiological, Oncological, Pathological Sciences, Policlinico Umberto I, Sapienza University of Rome - Rome (Italy)

Raffaella Casolino

Technical Officer at the WHO headquarter in Geneva, as part of the Cancer Control team, and honorary clinical senior lecturer at the School of Cancer Science of University of Glasgow - Geneva (Switzerland)

Edoardo Crimini

Medical Oncologist at Department of Medical Oncology, European Institute of Oncology - Milan (Italy)



Giuseppe Curigliano

Full Professor of Medical Oncology, Department of Oncology and Hemato-Oncology, University of Milano. Director Division of Early Drug Development for Innovative Therapies European Institute of Oncology, IRCCS - Milan (Italy)

Ruggero De Maria Marchiano

Institute of General Pathology, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS, Comprehensive Cancer Center Rome; Alliance Against Cancer ACC - Rome (Italy)

Massimo Di Maio

AIOM President; Associate Professor of Medical Oncology at the University of Turin (Italy)

Ken Herrmann

Professor of Nuclear Medicine at the Universitätsklinikum Essen; Adjunct Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA) - Essen (Germany)

Clifford A. Hudis

Breast Medical Oncologist at Memorial Sloan Kettering Cancer Centre - New York (USA)

John Kerk

Associate Director Stem Cell Technology - Velocigene - Regeneron - Tarrytown (USA)

Sherene Loi

Consultant Medical Oncologist, Breast Unit; Head, Translational Breast Cancer Genomics and Therapeutics Lab (Loi Lab); Breast Stream Lead, Parkville Precinct Cancer Clinical Trials Unit at Peter MacCallum Cancer Center - Victoria (AUSTRALIA)

Cristian Massacesi

Chief Medical Officer (CMO) di Bristol Myers Squibb - New York (USA)

Paolo Marchetti

Head of Scientific Department Istituto Dermopatico dell'Immacolata IRCCS - Rome (Italy)



Antonio Marra

Medical Oncologist at the Division of Early Drug Development for Innovative Therapies European Institute of Oncology, IRCC - Milan (Italy)

Nello Martini

Ricerca e Salute Foundation, Rome (Italy)

Funda Meric-Bernstam

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine MD Anderson Cancer Center - Houston (USA)

Robert Giovanni Nisticò

Full Professor of Pharmacology, Dept. of Biology at Tor Vergata University - Rome (Italy)

Thomas Powles

Professor of Genitourinary Oncology; Director, Barts Cancer Centre at St. Bartholomew's Hospital; Lead for Solid Tumour Research - London (UK)

Giancarlo Pruneri

Head, Department of Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale Tumori; Full Professor in Pathology, University of Milan, School of Medicine; Editor-in-Chief Tumori Journal - Milan (Italy)

Simone Scagnoli

Doctor of Oncology MD, PhD at Sapienza University - Rome (Italy)

Lillian L. Siu

Senior Scientist, "Princess Margaret Cancer Centre", Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre - Toronto (CANADA)

Vivek Subbiah

Chief, Early-Phase Drug Development at Sarah Cannon Research Institute - Zurich (Swiss)



Charles Swanton

Deputy Clinical Director; Cancer Evolution and Genome Instability Laboratory at the Francis Crick Institute - London (UK)

Giuseppe Tonini

Medical Oncology Unit, Policlinico Universitario Campus Bio-medico Foundation - Rome (Italy)

Giampaolo Tortora

Full Professor of Medical Oncology, Faculty of Medicine and Surgery, Catholic University of the Sacred Heart, Rome Campus - Rome (Italy)

Christoph Benedikt Westphalen

Head "Molecular Diagnostics and Therapy Programme" and the "Molecular Tumour Board" at the University of Munich, Germany. Medical lead for early phase clinical trials in medical oncology - Munich (Germany)

Timothy A. Yap

Ramson Horne, Jr. Endowed Professor for cancer research. VP and Head of Clinical Development, Therapeutics Discovery Division. The University of Texas M.D. Anderson Cancer Center - Houston (USA)



General Information

Presidents: *Giuseppe Curigliano, Paolo Marchetti, Andrea Botticelli*

Congress Venue: Villa Aurelia - Largo di Porta San Pancrazio, 2 - Rome

Didactika S.r.l. Piazza della Trasfigurazione, 8/a - 00151 Rome

CME Provider n. 4795 ref. n. 467234 and n. 482200

CME Credits: 9,1

This event is open to biologists, medical doctors, surgeons, physiotherapist and psychologists.

Disciplines:

Dermatology and Venereology; Hematology; Medical Genetics; Internal Medicine; Oncology; Radiotherapy; General Surgery; Endocrinology, Gynecology and Obstetrics; Pathological Anatomy; Clinical Biochemistry; Pharmacology and Clinical Toxicology; Clinical Pathology (Clinical Chemical Analysis Laboratory and Microbiology); Radiology; General Medicine (Family Practitioners); Palliative Care; Epidemiology.

To obtain the CME credits, the participant should be present for at least 80% of the total duration of the Congress, fill in all the forms and pass the final CME test. At the end of the Congress, the organizing secretariat will issue a certificate of attendance.

Registration:

Registration is free and necessary. To register for the Congress, please visit www.didactika.it and follow the registration instructions.

Registration includes:

Access to all scientific sessions. Certificate of attendance.

This congress will be held in person for a maximum of 150-200 participants.



Thanks to the unrestricted contribution of:

REGENERON

SCIENCE TO MEDICINE®

